
    
      ATYR1940-C-004 is a Phase1b/2 open-label intrapatient study dose escalation study aiming to
      evaluate the safety, tolerability, immunogenicity, biological activity of intravenous
      ATYR1940, administered once weekly for 8 weeks, then twice a weekly for 4 weeks in adult
      patients with LGMD2B and FSHD. Approximately 8 LGMD2B and 8 FHSD patients will be enrolled.
    
  